Articles tagged with Lung Tumors
The new T classification is based on tumor size and has been validated as appropriate for pathologic findings. The study found significant differences in survival rates among revised T subsets, highlighting the importance of the revised TMN classification for lung cancer treatment planning.
A rapid decline in PET scan activity is correlated with good local tumor control and better lung cancer outcomes. Higher pre-treatment metabolic activity and tumor size are associated with increased risk of death from lung cancer.
Researchers from the University of Texas M. D. Anderson Cancer Center have discovered that Th17 cells can awaken the immune system to fight cancer. In preclinical studies, mice with normal levels of Th17 showed suppressed tumor growth in lung metastatic melanoma tumors, while those without Th17 experienced aggressive cancer growth.
Researchers at the Mayo Clinic have discovered that the lung cancer oncogene PKCiota is necessary for the proliferation of lung cancer stem cells. The study found that an agent called aurothiomalate substantially inhibits growth of these cancer stem cells, suggesting a potential new treatment target.
Researchers have discovered a small peptide that stops lung cancer tumors from growing by inhibiting blood vessel formation. The study showed significant reduction in tumor size and fewer blood vessels compared to untreated animals.
A recent study published in the Journal of Thoracic Oncology found that tumor size and level of visceral pleura invasion significantly impact the survival of non-small cell lung cancer (NSCLC) patients. Researchers analyzed data from over 9,700 surgical resection cases and divided patients into nine groups based on tumor size and VPI.
Innate Therapeutics' novel microparticle-based immune response modifier MIS416 significantly inhibited tumor growth and metastasis in lung and breast cancers. Administered as an adjunct to localized tumor irradiation, MIS416 demonstrated synergistic activity against recurrent lung tumors.
A retrospective analysis found that multiple lung tumors in patients often arise from a single cancer cell, suggesting multifocal lung cancers should be classified as advanced-stage cancers. The study analyzed 70 tumor samples and concluded that 77% of patients had multiple tumors originating from a single clone.
Research suggests that high intake of inorganic phosphates, found in processed foods, can stimulate lung cancer development and growth. Dietary regulation of phosphates may play a critical role in treatment and prevention of the disease.
A collaborative study of nearly 200 lung cancer patients has identified over 1,000 genetic alterations and pinpointed 26 frequently altered genes. The research highlights the importance of integrating multiple large-scale approaches to highlight key molecular defects in lung tumors.
Researchers found that patients with specific EGFR gene mutations can live almost two years on average when treated with erlotinib, outperforming chemotherapy by two-to-three fold. The study identified a subgroup of 15-22% patients who can benefit from targeted therapies
A study published in The Lancet Oncology found that radiofrequency ablation can be an effective treatment for small lung tumors, with a confirmed complete response rate of 88% and overall survival rates ranging from 48-75%. The procedure was also shown to have a low risk of complications, including pneumothorax and pleural effusion.
Researchers at M. D. Anderson Cancer Center have identified a tumor-suppressor gene that suppresses lung tumors in mice and could provide new approaches for lung cancer prevention, diagnosis, and treatment. The GPRC5A gene is under-expressed in human lung cancer cells and its expression was found to be lower in 61% of human non-small c...
Researchers develop synthetic compound that promotes death of lung-cancer cells and tumors by mimicking natural 'death-promoting' protein Smac. The compound was effective against nearly one-quarter of lung-cancer cell lines tested, with some breast cancer and melanoma cells also showing sensitivity.
A prospective study found that quality of life surpasses classic predictors like disease stage and tumor size in determining survival. Patients with better quality of life scores had a significantly higher rate of survival.
A new study led by Duke University researchers found distinct differences in tumor susceptibility to chemotherapy drugs based on gene expression profiling. This allows clinicians to predict which patients are most likely to respond to standard therapy and offers alternative options for those not responding.
Researchers found a new lung tumor-suppressor gene, LKB1, that blocks key steps of lung cancer development in mice. The study suggests LKB1 may be more powerful than other known suppressors and could influence non-small cell lung cancer diagnosis and treatment.
Researchers found that talc stimulates healthy cells to produce endostatin, a hormone that inhibits tumor growth and kills tumor cells. The study reveals talcum powder's potential as a therapeutic agent for metastatic lung cancer, offering new hope for patients with incurable disease.
Patients undergoing minimally invasive lung cancer surgery experience shorter hospital stays and accelerated recovery times compared to traditional open surgery. This approach also improves chemotherapy delivery, reducing delays and increasing treatment efficacy.
A study at Ohio State University found that losing one copy of the Wwox gene greatly increases lung cancer risk in mice. Even with one working copy, they developed five times more lung tumors than those with two copies.
A new mouse model of non-small cell lung cancer validates MEK inhibitors as a potential treatment option. The model, developed by Dr. Martin McMahon and colleagues, shows that MEK inhibition can halt tumor progression in early-stage lung tumors.
A new study shows that shaped-beam radiosurgery can treat the smallest lung tumors, allowing patients to live disease-free for years. Researchers found that 91% of treated tumors never progressed and 25% of patients were cancer-free after three years.
Researchers have discovered three new subtypes of non-small-cell lung cancer tumors based on genetic patterns, which correlate with clinical outcomes such as survival rates and metastatic patterns. This finding may lead to more personalized treatment approaches for patients.
A radiation-armed robot, CyberKnife with Synchrony system, effectively treats lung tumors within a short treatment period of 1-3 sessions. This technology delivers intense focused x-ray beams, causing tumors to absorb more radiation than conventional radiotherapy, leading to rapid tumor destruction.
A study published in PLOS Medicine found that gene expression patterns in human lung tumors most similar to those seen in early mouse lung development stages predict poorer outcomes for lung cancer patients. The researchers developed a classification system based on genomic analysis, which may help improve treatment options.
A study found that 17% of patients with non-small cell lung cancer experienced a significant change in tumor size after just 31 days of chemotherapy. Tumors either grew or shrunk by 20-48% during this period, prompting changes to treatment plans.
Researchers found that follow-up PET scans showed persistent tumor activity in seven out of eleven RFA treatments. This suggests that FDG-PET is a more accurate method for evaluating tumor destruction than CT alone.
A study found that a high level of CRP is associated with an increased risk of developing progressive precancerous lesions in the lungs. The researchers believe that this inflammatory biomarker could help identify individuals at high risk for non-small cell lung cancer and potentially treat them with chemopreventive agents.
Researchers analyzed 28,689 cases of non-small cell lung cancer, finding a stronger association between tumor size and metastasis for solid tumors. The study suggests that smaller tumor sizes are associated with higher curability rates, even for micrometastases undetectable by current techniques.
A new antibody profiling technique has been developed to identify five protein markers that can detect lung cancer with high accuracy. The technique achieved 90% sensitivity and 95% specificity in identifying cancerous versus non-cancerous patient samples.
A new study published in PLOS Medicine found that patients with KRAS mutations do not respond to targeted therapy drugs erlotinib and gefitinib. Analyzing tumors for EGF receptor and KRAS mutations may be crucial to predicting treatment effectiveness.
Researchers studied 155 image-guided RFA lung procedures on 126 medically inoperable patients with 163 lesions, finding low complication rates and improved morbidity. The outpatient procedure effectively controls small tumors, allowing patients to avoid surgery and improve their quality of life.
A new imaging technology developed by GE Medical Systems precisely tracks lung tumor motion, enabling more accurate radiation therapy. Tumors in the lower lobes and attached to the posterior side of the lungs tend to move more than others.
Researchers found RFA improves quality of life for inoperable lung cancer patients, with complete ablations resulting in tumor size reduction and minimal enhancement on follow-up CT. Pattern enhancement and changes in tumor size are key indicators of successful RFA on CT.
In a study of 18 patients with inoperable lung tumors, radiofrequency ablation (RFA) was found to eradicate lung tumors with no relapse in 94% of cases. Minor complications, including pneumothorax, were treated successfully, and the procedure offered benefits such as low costs, short hospitalization times, and good patient tolerance.
Researchers at Mayo Clinic used a human antibody to stimulate dendritic cells and induce an immune response against malignant melanoma. The study showed that the antibody treatment resulted in consistently strong and often curative effects in mice, with 69% of treated mice being tumor-free.
A recent analysis of lung cancer screening studies found that CT scans do not save lives and may even be counterproductive. The study's authors estimated that between 4.1 and 5.5 patients per thousand would die of lung cancer after screening, similar to the mortality rate without screening.
Researchers found that combining CT and PET scans significantly enhances radiologists' abilities to precisely define tumor locations for radiation treatments. This improves the efficacy of treatment and limits side effects in non-small-cell lung cancer patients. PET-CT scanning units are now available at hundreds of hospitals nationwide.
Researchers developed a novel method to compare genetic changes in developing mice with those in medulloblastoma, revealing common features with early developmental stages. This study provides a foundation for further research into tumor diagnosis and prognosis.
Researcher Dr. Mitra has developed an optical tomography method to locate lung tumors using short-pulse lasers. The technique yields physiological information with higher resolution and a safer system than traditional methods.
A study published in The Journal of Nuclear Medicine found that 18F-FLT PET scans are more accurate than 18F-FDG PET scans in differentiating between cancerous and non-cancerous lung tumors. However, the researchers noted that 18F-FDG is still a reliable tool for staging tumors.
Radiofrequency ablation has shown promising results in treating advanced lung cancer, with significant pain reduction and improved survival rates. The procedure involves using extreme heat to destroy or slow the growth of tumors, and can be used as an alternative to surgery, chemotherapy, and radiation therapy.
Researchers have developed a new procedure that treats spinal tumors more effectively by using intensity modulated radiation and image-guided techniques. This allows for precise treatment with minimal exposure to healthy tissue, resulting in rapid symptom relief within two weeks.
Researchers identified three genetic subtypes of lung adenocarcinomas, each associated with different survival rates and treatment outcomes. The study could improve diagnosis and treatment options for patients with this aggressive form of lung cancer.
Researchers found that gene Rb2 inhibits angiogenesis, a critical process for tumor growth. The study suggests that Rb2 may be used to treat lung cancer and glioblastoma by blocking blood vessel formation.